Luke Peterson

Bimekizumab versus Secukinumab in Plaque Psoriasis

Kristian Reich, Richard B. Warren, Mark Lebwohl et al. · New England Journal of Medicine · 2021 · 368 citations

Bimekizumab versus Adalimumab in Plaque Psoriasis

Richard B. Warren, Andrew Blauvelt, Jerry Bagel et al. · New England Journal of Medicine · 2021 · 217 citations

Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial

Kim Papp, Joseph F. Merola, Alice B. Gottlieb et al. · Journal of the American Academy of Dermatology · 2018 · 187 citations · Full text

Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study

Josef S Smolen, Gerd‐Rüdiger Burmester, Bernard Combe et al. · The Lancet · 2016 · 173 citations

Rheumatoid Disorder, Rheumatology, Rheumatic Diseases +7

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)

Alice B. Gottlieb, Andrew Blauvelt, Diamant Thaçi et al. · Journal of the American Academy of Dermatology · 2018 · 151 citations · Full text